This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alcaide, F.
Right arrow Articles by Martín, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alcaide, F.
Right arrow Articles by Martín, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2001, p. 624-626, Vol. 45, No. 2
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.2.624-626.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activities of the New Ketolide HMR 3647 (Telithromycin) in Comparison with Those of Eight Other Antibiotics against Viridans Group Streptococci Isolated from Blood of Neutropenic Patients with Cancer

Fernando Alcaide,1,* Miguel Angel Benítez,1 Jordi Carratalà,2 Francesc Gudiol,2 Josefina Liñares,1 and Rogelio Martín1

Departments of Microbiology1 and Infectious Diseases,2 Hospital "Prínceps d'Espanya," Ciutat Sanitària i Universitària de Bellvitge, 08907 L'Hospitalet de Llobregat, Barcelona, Spain

Received 12 June 2000/Returned for modification 18 October 2000/Accepted 7 November 2000

The in vitro activities of the ketolide telithromycin and eight other antibiotics were tested against 77 strains of viridans group streptococci isolated from blood samples of neutropenic patients. Thirty-one (40.3%) of the strains were resistant to penicillin G, and 27 (35.1%) were resistant to erythromycin A. Telithromycin (MIC range of <= 0.03 to 1 µg/ml) was the most active antimicrobial tested. These data suggest that telithromycin could be useful for treatment of viridans group streptococcal bacteremia in neutropenic patients with cancer.

* Corresponding author. Mailing address: Servei de Microbiologia, Hospital "Princeps d'Espanya," Ciutat Sanitària i Universitària de Bellvitge, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. Phone: 34-93-2607930. Fax: 34-93-2607547. E-mail: falcaide{at}csub.scs.es.

Antimicrobial Agents and Chemotherapy, February 2001, p. 624-626, Vol. 45, No. 2
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.2.624-626.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Brown, D. F. J., Hope, R., Livermore, D. M., Brick, G., Broughton, K., George, R. C., Reynolds, R., on behalf of the BSAC Working Parties on Resistanc, (2008). Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 62: ii75-ii85 [Abstract] [Full Text]  
  • Han, X. Y., Kamana, M., Rolston, K. V. I. (2006). Viridans Streptococci Isolated by Culture from Blood of Cancer Patients: Clinical and Microbiologic Analysis of 50 Cases. J. Clin. Microbiol. 44: 160-165 [Abstract] [Full Text]  
  • Rodriguez-Avial, I., Rodriguez-Avial, C., Culebras, E., Picazo, J. J. (2005). In Vitro Activity of Telithromycin against Viridans Group Streptococci and Streptococcus bovis Isolated from Blood: Antimicrobial Susceptibility Patterns in Different Groups of Species. Antimicrob. Agents Chemother. 49: 820-823 [Abstract] [Full Text]  
  • Lyytikainen, O., Rautio, M., Carlson, P., Anttila, V.-J., Vuento, R., Sarkkinen, H., Kostiala, A., Vaisanen, M.-L., Kanervo, A., Ruutu, P., on behalf of the Hospital Infection Surveillance T, (2004). Nosocomial bloodstream infections due to viridans streptococci in haematological and non-haematological patients: species distribution and antimicrobial resistance. J Antimicrob Chemother 53: 631-634 [Abstract] [Full Text]  
  • Seppala, H., Haanpera, M., Al-Juhaish, M., Jarvinen, H., Jalava, J., Huovinen, P. (2003). Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J Antimicrob Chemother 52: 636-644 [Abstract] [Full Text]  
  • Facklam, R. (2002). What Happened to the Streptococci: Overview of Taxonomic and Nomenclature Changes. Clin. Microbiol. Rev. 15: 613-630 [Abstract] [Full Text]  
  • Pihlajamaki, M., Kataja, J., Seppala, H., Elliot, J., Leinonen, M., Huovinen, P., Jalava, J. (2002). Ribosomal Mutations in Streptococcus pneumoniae Clinical Isolates. Antimicrob. Agents Chemother. 46: 654-658 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»